Morgan Stanley
ICVX

Morgan Stanley’s Icosavax, Inc. Common Stock ICVX Stock Holding History

Morgan Stanley’s Portfolio ICVX Stock Details ICVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-131,606
Closed -$2.07M – 8076
2023
Q4 		$2.07M Buy
131,606
+97,021
+281% +$934K ﹤0.01% 4901
2023
Q3 		$268K Buy
34,585
+2,807
+9% +$23.3K ﹤0.01% 5448
2023
Q2 		$316K Buy
31,778
+7,439
+31% +$59.5K ﹤0.01% 5443
2023
Q1 		$141K Buy
24,339
+3,666
+18% +$31.7K ﹤0.01% 5863
2022
Q4 		$164K Buy
20,673
+1,427
+7% +$6.13K ﹤0.01% 5748
2022
Q3 		$61K Sell
19,246
-95,348
-83% -$596K ﹤0.01% 6321
2022
Q2 		$657K Buy
114,594
+69,866
+156% +$545K ﹤0.01% 5272
2022
Q1 		$315K Buy
44,728
+3,494
+8% +$54.9K ﹤0.01% 5663
2021
Q4 		$944K Buy
41,234
+5,340
+15% +$138K ﹤0.01% 5114
2021
Q3 		$1.06M Buy
+35,894
New +$1.22M ﹤0.01% 5008

Morgan Stanley's ICVX Position: Q1 2024 in Review

Morgan Stanley sold out of Icosavax, Inc. Common Stock (ICVX) in Q1 2024, closing a stake of 131,606 shares — an estimated $2.07M sold.

Morgan Stanley first reported a position in ICVX in Q3 2021 and held it in 10 quarters. The position peaked at $2.07M in Q4 2023. 0 funds tracked by Wall St. Rank hold ICVX as of Q1 2024.

  • Morgan Stanley reported no remaining Icosavax, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Morgan Stanley sold 131,606 Icosavax, Inc. Common Stock shares in Q1 2024, an estimated $2.07M.
  • Morgan Stanley first reported a position in Icosavax, Inc. Common Stock in Q3 2021 and held it in 10 quarters.
  • Morgan Stanley's Icosavax, Inc. Common Stock position peaked at $2.07M in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Icosavax, Inc. Common Stock as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.